Search
Sagimet Biosciences Inc
SGMTAdd to Watchlist
9.110USD
-1.310-12.57%
Close 09-24 16:00（ET）
562.54MMarket Cap
LossP/E TTM
About Sagimet Biosciences Inc Company
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.
Sagimet Biosciences Inc Profile
Ticker SymbolSGMT
Company nameSagimet Biosciences Inc
IPO dateJul 14, 2023
CEOHappel (David)
Number of employees14
Security typeOrdinary Share
Fiscal year-endJul 14
Address155 Bovet Rd., Suite 303
CitySAN MATEO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94402
Phone16505618600
Websitehttps://sagimet.com/
Ticker SymbolSGMT
IPO dateJul 14, 2023
CEOHappel (David)
Company Executives of Sagimet Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. David Happel
Mr. David Happel
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
214.12K
-29.91%
Mr. David Happel
Mr. David Happel
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
214.12K
-29.91%
Mr. David Happel
Mr. David Happel
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
214.12K
-29.91%
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
131.64K
--
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
131.64K
--
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
131.64K
--
Ms. Elizabeth Rozek
Ms. Elizabeth Rozek
Chief Compliance Officer, General Counsel
Chief Compliance Officer, General Counsel
59.35K
-17.77%
Ms. Elizabeth Rozek
Ms. Elizabeth Rozek
Chief Compliance Officer, General Counsel
Chief Compliance Officer, General Counsel
59.35K
-17.77%
Ms. Elizabeth Rozek
Ms. Elizabeth Rozek
Chief Compliance Officer, General Counsel
Chief Compliance Officer, General Counsel
59.35K
-17.77%
Mr. Thierry Chauche
Mr. Thierry Chauche
Chief Financial Officer
Chief Financial Officer
42.69K
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. David Happel
Mr. David Happel
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
214.12K
-29.91%
Mr. David Happel
Mr. David Happel
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
214.12K
-29.91%
Mr. David Happel
Mr. David Happel
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
214.12K
-29.91%
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
131.64K
--
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
131.64K
--
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
131.64K
--
FAQs
Who are the top five shareholders of Sagimet Biosciences Inc?
The top five shareholders of Sagimet Biosciences Inc are: Mr. David Happel
How many institutions hold shares of Sagimet Biosciences Inc (SGMT)?
As of 2026Q1, 231 institutions hold shares of Sagimet Biosciences Inc, with a combined market value of approximately 15.88M, accounting for 25.99% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -5273084.00.